Use of cathepsin K inhibitors in severe bone loss diseases

Details for Australian Patent Application No. 2004290874 (hide)

Owner Novartis AG

Inventors Gamse, Rainer; Missbach, Martin; Trechsel, Ulrich

Agent Davies Collison Cave

Pub. Number AU-A-2004290874

PCT Pub. Number WO2005/049028

Priority 03026430.3 19.11.03 EP

Filing date 19 April 2004

Wipo publication date 2 June 2005

International Classifications

A61K 31/00 (2006.01)

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

Event Publications

1 June 2006 PCT application entered the National Phase

  PCT publication WO2005/049028 Priority application(s): WO2005/049028

16 October 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004290876-Use of perfluoropolyethers phosphates as stabilizing agents for polyphenols in cosmetic and/or dermatological compositions

2004290869-Therapeutic use of factor XI